Market Research Logo

Hemostats - Medical Devices Pipeline Assessment, 2018

Hemostats - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Hemostats - Medical Devices Pipeline Assessment, 2018 provides an overview of Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Hemostats Overview
3 Products under Development
3.1 Hemostats - Pipeline Products by Stage of Development
3.2 Hemostats - Pipeline Products by Segment
3.3 Hemostats - Pipeline Products by Territory
3.4 Hemostats - Pipeline Products by Regulatory Path
3.5 Hemostats - Pipeline Products by Estimated Approval Date
3.6 Hemostats - Ongoing Clinical Trials
4 Hemostats - Pipeline Products under Development by Companies
4.1 Hemostats Companies - Pipeline Products by Stage of Development
4.2 Hemostats - Pipeline Products by Stage of Development
5 Hemostats Companies and Product Overview
5.1 3-D Matrix Ltd Company Overview
5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.2 Angiotech Pharmaceuticals Inc Company Overview
5.2.1 Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Anika Therapeutics Inc Company Overview
5.3.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 APRUS Bio-Medical Innovations Pvt Ltd Company Overview
5.4.1 APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.5 Arch Therapeutics Inc Company Overview
5.5.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.6 Baxter International Inc Company Overview
5.6.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Beth Israel Deaconess Medical Center Inc Company Overview
5.7.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Biomedica Management Corp Company Overview
5.8.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview
5.9 Biom'Up SAS Company Overview
5.9.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview
5.10 C. R. Bard Inc Company Overview
5.10.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 Cellphire Inc Company Overview
5.11.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 Ceramicos Para Aplicacoes Medicas SA Company Overview
5.12.1 Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview
5.13 Columbia University Company Overview
5.13.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
5.14 Covalent Medical, Inc. (Inactive) Company Overview
5.14.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.15 Covalon Technologies Ltd Company Overview
5.15.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.16 Cresilon Inc Company Overview
5.16.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 CryoLife Inc Company Overview
5.17.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview
5.18 Endomedix Incorporated Company Overview
5.18.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview
5.19 Entegrion Inc Company Overview
5.19.1 Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview
5.20 Ethicon US LLC Company Overview
5.20.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview
5.21 ETX Pharma Inc Company Overview
5.21.1 ETX Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Gamma Therapeutics Inc Company Overview
5.22.1 Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.23 GATT Technologies BV Company Overview
5.23.1 GATT Technologies BV Pipeline Products & Ongoing Clinical Trials Overview
5.24 gel-e Inc Company Overview
5.24.1 gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview
5.25 Haemostatix Ltd Company Overview
5.25.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.26 Hemostasis LLC Company Overview
5.26.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview
5.27 KeraNetics, LLC Company Overview
5.27.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.28 Leader Biomedical Europe BV Company Overview
5.28.1 Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview
5.29 LifeBond Ltd Company Overview
5.29.1 LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.30 Resorba GmbH Company Overview
5.30.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.31 Rice University Company Overview
5.31.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview
5.32 Sanofi Company Overview
5.32.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview
5.33 Sea Run Holdings Inc Company Overview
5.33.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 St Teresa Medical Inc Company Overview
5.34.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.35 The Medicines Company Overview
5.35.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview
5.36 Therus Corporation Company Overview
5.36.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.37 Thrombotargets Corp Company Overview
5.37.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview
5.38 United Health Products, Inc. Company Overview
5.38.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.39 University of Grenoble Alpes Company Overview
5.39.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview
5.40 Virginia Commonwealth University Company Overview
5.40.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
5.41 WNDM Medical Inc Company Overview
5.41.1 WNDM Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.42 Xcede Technologies Inc Company Overview
5.42.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Hemostats- Recent Developments
6.1 Jun 06, 2018: Advanced Medical Solutions announces retirement of CFO
6.2 Jun 05, 2018: Johnson & Johnson Announces Progress Toward Health for Humanity Goals
6.3 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value
6.4 May 31, 2018: Merit Medical Announces Leadership Change and Appointment of Interim CFO
6.5 May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi
6.6 May 28, 2018: Covalon Announces Major Corporate Initiatives and Second Quarter Results
6.7 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.8 May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
6.9 May 10, 2018: Partnership Agreement concluded with DEMEDIC regarding sales and marketing of absorbable local hemostat “PuraStat” in Argentina
6.10 May 09, 2018: Sanofi lays off 95 workers in Framingham
6.11 May 08, 2018: Arch Therapeutics Provides Update on Study Initiation and 510(k)
6.12 May 08, 2018: Arch Therapeutics Provides Update on Study Initiation and 510(k)
6.13 May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel
6.14 May 07, 2018: FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
6.15 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.16 May 07, 2018: Covalon Announces Major Sales Breakthrough - Wins Contracts with an Estimated Value of $100 Million Over a Three-Year Period
6.17 May 02, 2018: Biom’up Finalizes U.S. Commercial Organization to Support U.S. Launch of HEMOBLAST Bellows
6.18 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results
6.19 May 02, 2018: Anika Reports First Quarter 2018 Financial Results
6.20 May 01, 2018: United Health Products Expands Animal Testing for HemoStyp in Support of PMA Application, Human Trials to Follow
6.21 Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER
6.22 Apr 26, 2018: Baxter Reports First-Quarter 2018 Results And Increases Financial Outlook For Full-Year 2018
6.23 Apr 26, 2018: Stryker reports first quarter 2018 operating results
6.24 Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results
6.25 Apr 25, 2018: Merit Medical Reports First Quarter of 2018 Financial Results
6.26 Apr 24, 2018: Biom’up Has Trained 200 Surgeons in its International KOL-Led Program Ahead of HEMOBLAST Bellows Launch
6.27 Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
6.28 Apr 20, 2018: Cook Medical Appoints Christina Anne Vice President of Distribution Channel Management
6.29 Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results
6.30 Apr 16, 2018: Biom'up reports 2017 full-year results and provides corporate update
6.31 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
6.32 Apr 03, 2018: Wound Management Technologies Changes Name to WNDM Medical
6.33 Mar 29, 2018: Wound Management Technologies Announces Record Annual Sales Ending December 31, 2017 - Up 14% over 2016
6.34 Mar 28, 2018: Sanofi: Pre - quarterly Results Communication
6.35 Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition
6.36 Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros
6.37 Mar 20, 2018: LiDCO Group: End of third party UK Distribution agreement
6.38 Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson
6.39 Mar 19, 2018: United Health Products Forms Medical Advisory Board
6.40 Mar 14, 2018: Advanced Medical Solutions Group: Unaudited Preliminary Results for the year ended 31 December 2017
6.41 Mar 13, 2018: United Health Products Receives CE Mark Approval for HemoStyp
6.42 Mar 12, 2018: Arch Therapeutics Provides Update on 510(k)
6.43 Mar 12, 2018: Arch Therapeutics Provides Update on 510(k)
6.44 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results
6.45 Mar 06, 2018: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
6.46 Mar 05, 2018: Anika Therapeutics Names Joseph Darling As CEO And Director
6.47 Feb 28, 2018: Axiostat Chitosan Hemostatic Dressing gets USFDA approval
6.48 Feb 28, 2018: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2017; Merit Meets Range of 2017 Guidance; Gives 2018 Guidance
6.49 Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
6.50 Feb 27, 2018: Z-Medica Announces Appointment Of Eric Compton As CEO
6.51 Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
6.52 Feb 21, 2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results
6.53 Feb 15, 2018: Wound Management Technologies Announces J. Michael Carmena Appointed Chief Executive Officer
6.54 Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program
6.55 Feb 12, 2018: Covalon Announces Strong First Quarter Financial Results 2017
6.56 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance
6.57 Feb 05, 2018: United Health Products Announces Completion Of FDA PMA For HemoStyp
6.58 Feb 01, 2018: Baxter Reports 2017 Fourth-Quarter and Full-Year Results
6.59 Jan 30, 2018: United Health Products Issues Update on HemoStyp South Korea MFDS Application
6.60 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
6.61 Jan 30, 2018: Stryker reports 2017 results and 2018 outlook
6.62 Jan 25, 2018: Lohmann & Rauscher: Personnel Change in Executive Board of L&R
6.63 Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results
6.64 Jan 22, 2018: United Health Products Provides FDA Update
6.65 Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
6.66 Jan 11, 2018: Xcede Hemostatic Patch Clinical Trial Dossier Submitted to Groningen-based Medical Ethical Review Committee (MREC) in Anticipation of First-in-Human Clinical Trial
6.67 Jan 09, 2018: New Absorbable Adjunctive Hemostat from Ethicon Helps Surgeons Control Disruptive Bleeding more Efficiently
6.68 Jan 09, 2018: United Health Products Gains Patent Protection Extension for HemoStyp
6.69 Jan 09, 2018: Stryker provides 2017 preliminary net sales results
6.70 Jan 08, 2018: Z-Medica Officially Launches QuikClot Control+
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Hemostats - Pipeline Products by Stage of Development
Table 2: Hemostats - Pipeline Products by Segment
Table 3: Hemostats - Pipeline Products by Territory
Table 4: Hemostats - Pipeline Products by Regulatory Path
Table 5: Hemostats - Pipeline Products by Estimated Approval Date
Table 6: Hemostats - Ongoing Clinical Trials
Table 7: Hemostats Companies - Pipeline Products by Stage of Development
Table 8: Hemostats - Pipeline Products by Stage of Development
Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 10: PuraStat Hemostat - Product Status
Table 11: PuraStat Hemostat - Product Description
Table 12: TDM-511 - Product Status
Table 13: TDM-511 - Product Description
Table 14: 3-D Matrix Ltd - Ongoing Clinical Trials Overview
Table 15: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery
Table 16: PuraStat Hemostat - Randomized Controlled Trial Comparing Purastat to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection
Table 17: Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Hemaseel Thrombin Haemostatic Agent - Product Status
Table 19: Hemaseel Thrombin Haemostatic Agent - Product Description
Table 20: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Hemostatic Patch - Product Status
Table 22: Hemostatic Patch - Product Description
Table 23: APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Deep Wound Hemostat - Product Status
Table 25: Deep Wound Hemostat - Product Description
Table 26: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: AC5 Surgical Hemostatic Device - Product Status
Table 28: AC5 Surgical Hemostatic Device - Product Description
Table 29: AC5 Surgical Hemostatic Device - Internal Use - Product Status
Table 30: AC5 Surgical Hemostatic Device - Internal Use - Product Description
Table 31: AC5 Topical Gel - Product Status
Table 32: AC5 Topical Gel - Product Description
Table 33: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Hemopatch - Product Status
Table 35: Hemopatch - Product Description
Table 36: Baxter International Inc - Ongoing Clinical Trials Overview
Table 37: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (more than 5 Days - PAL)
Table 38: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant
Table 39: Hemopatch - A Randomized, Controlled, Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection
Table 40: Hemopatch - A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Table 41: Hemopatch - Assessment of the Usefulness of Hemopatch in Coronary Artery Bypass Graft Surgery
Table 42: Hemopatch - Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection
Table 43: Hemopatch - Hemopatch Performance Evaluation: A Prospective Observational Registry
Table 44: Hemopatch - Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the use of the New Hemostatic Patch Hemopatch in Patients undergoing Surgical Liver Resection
Table 45: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial
Table 46: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH
Table 47: Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Portable Wound Hemostasis System - Product Status
Table 49: Portable Wound Hemostasis System - Product Description
Table 50: Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 51: ClotFoam - Product Status
Table 52: ClotFoam - Product Description
Table 53: ClotGel - Product Status
Table 54: ClotGel - Product Description
Table 55: ClotSpray - Product Status
Table 56: ClotSpray - Product Description
Table 57: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Hemoblast Bellows - Product Status
Table 59: Hemoblast Bellows - Product Description
Table 60: HEMOSNOW - Product Status
Table 61: HEMOSNOW - Product Description
Table 62: Biom'Up SAS - Ongoing Clinical Trials Overview
Table 63: Hemoblast Bellows - Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of Hemoblast Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries
Table 64: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 65: New Hemostat 1 - Product Status
Table 66: New Hemostat 1 - Product Description
Table 67: New Hemostat 2 - Product Status
Table 68: New Hemostat 2 - Product Description
Table 69: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Thromboderm - Product Status
Table 71: Thromboderm - Product Description
Table 72: Thrombosomes - Product Status
Table 73: Thrombosomes - Product Description
Table 74: Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview
Table 75: HemoKi - Product Status
Table 76: HemoKi - Product Description
Table 77: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
Table 78: Hemostatic Wound Dressing - Product Status
Table 79: Hemostatic Wound Dressing - Product Description
Table 80: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 81: CovaSTAT - Product Status
Table 82: CovaSTAT - Product Description
Table 83: Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 84: ColActive THP - Product Status
Table 85: ColActive THP - Product Description
Table 86: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status
Table 87: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description
Table 88: Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 89: TRAUMAGEL - Product Status
Table 90: TRAUMAGEL - Product Description
Table 91: VETIGEL - Product Status
Table 92: VETIGEL - Product Description
1.2 List of Figures
Figure 1: Hemostats - Pipeline Products by Stage of Development
Figure 2: Hemostats - Pipeline Products by Segment
Figure 3: Hemostats - Pipeline Products by Territory
Figure 4: Hemostats - Pipeline Products by Regulatory Path
Figure 5: Hemostats - Pipeline Products by Estimated Approval Date
Figure 6: Hemostats - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report